by Dan Roberts (updated April 2009) A new type of anti-VEGF drug called “small interference RNA (siRNA),” is showing promise in its ability to turn off genes that cause wet AMD. A preliminary primate study in early 2004 showed that, at the highest dose used in the study siRNA (formerly called RNAi) “reduced the incidence [Read More]
Category: Research and Developments
Brain Reorganizes to Adjust for Loss of Vision
Atlanta (November 20, 2008) – A new study from Georgia Tech shows that when patients with macular degeneration focus on using another part of their retina to compensate for their loss of central vision, their brain seems to compensate by reorganizing its neural connections. Age related macular degeneration is the leading cause of vision loss [Read More]
Interleukin-6 and Interleukin-8 Linked to Dry AMD
by Dan Roberts (Updated November 10, 2008) Concentration of two cytokines, interleukin-6 and interleukin-8, have been found in two different studies to be potential biomarkers for incidence of dry AMD. Cytokines are signaling compounds in the cells that are involved in a variety of immunological, inflammatory, and infectious diseases. Janice C. Law, MD, and her [Read More]
POT-4 for Treatment of AMD
by Dan Roberts (Updated September 29, 2008) Potentia Pharmaceuticals, Inc. announced on March 20, 2007 that it was entering the clinical phase of development of POT-4 for treatment of age-related macular degeneration (AMD). According to the researchers, POT-4, a synthetic peptide, shuts down the complement activation system that can lead to local inflammation, tissue damage [Read More]
Pearls from Recent Studies on Low Vision Rehabilitation and Psychosocial Issues
Research of interest to the AMD Community as presented at Vision 2008, Montreal, Canada Selected and Summarized by Dan Roberts, Director, MD Support These findings are derived by the referenced authors based solely upon the results of their respective studies. In every case, more research is recommended before final conclusions can be drawn. Pearl #1. [Read More]